Driven to extend the lives of cancer patients
Celcuity was founded in 2012 by Brian Sullivan and Lance Laing, PhD, to develop a better way to diagnose and treat the cellular abnormalities that drive tumor growth. Our team of drug development scientists, biochemists, molecular biologists, and diagnostics experts are advancing new targeted therapies for cancer using an integrated therapeutic and companion diagnostic strategy that leverages our CELsignia platform.
Integrated therapeutic and companion diagnostic strategy to improve patient outcomes
Gedatolisib, our potential first-in-class pan-PI3K/mTOR inhibitor, is currently being developed for the treatment of patients with ER+/HER2-negative metastatic breast cancer. We expect to evaluate additional indications in other tumor types.
With our CELsignia companion diagnostics, we are collaborating with leading pharmaceutical companies to evaluate their targeted therapeutics in CELsignia-selected patients. Five Phase 2 trials are currently underway.